Share on LinkedInShare on LinkedIn

ARTICLE · 14 SEPTEMBER 2021

Federal Circuit Issues Second GSK v. Teva Opinion On "Skinny" Label-Based Inducement

The Federal Circuit's August 5, 2021 ruling in GlaxoSmithKline LLC v. Teva Pharm. USA, Inc. (link to issued opinion), is an important development in the law of "skinny"...

United StatesIntellectual Property

The Federal Circuit's August 5, 2021 ruling in GlaxoSmithKline LLC v. Teva Pharm. USA, Inc. (link to issued opinion), is an important development in the law of "skinny" generic pharmaceutical labels and induced infringement claims. See GlaxoSmithKline LLC v. Teva Pharm. USA, Inc., 7 F.4th 1320 (Fed. Cir. 2021) ("GSK II") (Google Scholar link). Read on for important aspects of the majority's opinion and Judge Prost's dissent.

Background on Section viii Carve Outs. ANDA filers can seek approval for generic products with labels that "carve out" patented indications. Those labels are commonly referred to as "skinny labels" or "section viii carve outs" (the applications require a statement under Section 505(j)(2)(A)(viii) of the FDCA, 21 U.S.C. § 355(j)(2)(A)(viii)).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from